This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

A Better Treatment for Advanced-Stage Hodgkin’s Lymphoma?

List of authors.
  • Dan L. Longo, M.D.,
  • and James O. Armitage, M.D

Treatment for patients with Hodgkin’s lymphoma is one of the success stories of modern medicine. A once uniformly fatal disorder is now curable, even in an advanced stage, in the great majority of patients. In fact, particularly in limited-stage Hodgkin’s lymphoma, much of the therapeutic focus is on maintaining the high probability of cure while reducing the incidence of toxic effects. How little therapy can we give without losing efficacy? For patients with advanced-stage, high-risk disease, debates regarding the best currently available approach have centered on the “old standard” ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) regimen,1 the very intensive escalated . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.

This editorial was published on July 13, 2022, at NEJM.org.

Author Affiliations

From the University of Nebraska, Omaha (J.O.A.).